2024 FDA DCT Guidance
Clinical ink provides insights for the 2024 FDA’s Guidance for Conducting Clinical Trials with Decentralized Elements Decentralized Clinical Trial (DCT).
2024 FDA DCT Guidance Read More...
Decentralized Clinical Trials
5 Key Takeaways from Recent FDA Draft Guidance on Decentralized Clinical Trials (DCTs)
Decentralized Clinical Trials (DCTs) have changed the way clinical research is conducted, transforming traditional approaches and introducing innovative methodologies.
5 Key Takeaways from Recent FDA Draft Guidance on Decentralized Clinical Trials (DCTs) Read More...
Clinical ink CBO Jonathan Andrus Selected as DTRA Co-Leader Chosen to Head Decentralized Trials & Research Alliance Regulatory Gap Initiative
Clinical ink CBO Jonathan Andrus Selected as DTRA Co-Leader Chosen to Head Decentralized Trials & Research Alliance Regulatory Gap Initiative Horsham, Pa.; August 12, 2021
McKesson Ventures Invests as Clinical ink Debuts Lunexis ePRO+ Solution Mixed Modalities Allow Users to Switch Between Smartphones, Tablets, and Web Any Time
HORSHAM, Pa.; Dec. 3, 2020 – Clinical ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module. Lunexis™ ePRO+ is part of a unified
